2019
DOI: 10.1007/s13346-019-00626-1
|View full text |Cite
|
Sign up to set email alerts
|

Protective effect of surface-modified berberine nanoparticles against LPS-induced neurodegenerative changes: a preclinical study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
14
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
6
3

Relationship

1
8

Authors

Journals

citations
Cited by 35 publications
(14 citation statements)
references
References 81 publications
0
14
0
Order By: Relevance
“…Neuroprotective effects of berberine have also been confirmed in animal models of Alzheimer's disease [83]. Berberine nanoparticles have shown protective effect against LPS-induced neurodegenerative changes [84]. Berberine confers neuroprotection in coping with focal cerebral ischemia by targeting inflammatory cytokines [85].…”
Section: Berberine From Berberis Aristata DCmentioning
confidence: 96%
“…Neuroprotective effects of berberine have also been confirmed in animal models of Alzheimer's disease [83]. Berberine nanoparticles have shown protective effect against LPS-induced neurodegenerative changes [84]. Berberine confers neuroprotection in coping with focal cerebral ischemia by targeting inflammatory cytokines [85].…”
Section: Berberine From Berberis Aristata DCmentioning
confidence: 96%
“…A good reduction in the Ī² -amyloid plaque was noticed. Soudi et al synthesized surface-modified berberine chitosan nanoparticles modified with the tween 80, PEG4000, and miltefosine against lipopolysaccharide [ 158 ]. The synthesized formulation showed the neuroprotective behavior against lipopolysaccharide-activated cerebral and associated liver changes in rats.…”
Section: Nanocarrier Containing Natural Product Used To Combat Alzheimer's Diseasementioning
confidence: 99%
“…BBR-NPs formulation (4 mg/kg, intraperitoneal, i.p.) was administered for 14 days, and on the 15 th -day lipopolysaccharide (LPS), BBR-NPs showed significant implication on the neuroprotective and hepatoprotective effects (Soudi et al, 2019). Another study demonstrated the pharmacokinetic parameters of BBR, following intragastric administration at a dose of 25 mg/kg in normal and diseased rats (post inflammatory irritable bowel syndrome).…”
Section: Preclinical Studiesmentioning
confidence: 99%